| For: |
Chen KY, Lin TJ, Lin CL, Lee HC, Wang CK, Wu DC. Hybrid |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v21/i36/10435.htm |
| Number | Citing Articles |
| 1 |
Li-Ya Zhou, Zhi-Qiang Song. Hybrid, sequential and concomitant therapies for <i>Helicobacter pylori</i> eradication: A systematic review and meta-analysis. World Journal of Gastroenterology 2016; 22(19): 4766-4775 doi: 10.3748/wjg.v22.i19.4766
|
| 2 |
Ping‐I Hsu, Feng‐Woei Tsay, John Y Kao, Nan‐Jing Peng, Kuo‐Wang Tsai, Tzung‐Jiun Tsai, Chao‐Hung Kuo, Sung‐Shuo Kao, Huay‐Min Wang, Yan‐Hua Chen, Chang‐Bih Shie, Deng‐Chyang Wu. Equivalent efficacies of reverse hybrid and concomitant therapies in first‐line treatment of Helicobacter pylori infection. Journal of Gastroenterology and Hepatology 2020; 35(10) doi: 10.1111/jgh.15034
|
| 3 |
Ayman Fathy El Sayed, Ayman Magd Eldin Mohammad Sadek, Walid Ahmed Ragab Abdelhamid. Comparison between Hybrid, Reverse Hybrid, and Non-Bismuth Levofloxacin Quadruple Regimens for Helicobacter Pylori Infection in Egypt: A Randomized Trial. Middle East Journal of Digestive Diseases 2021; 13(3) doi: 10.34172/mejdd.2021.229
|
| 4 |
Anthony O'Connor, Wolfgang Fischbach, Javier P. Gisbert, Colm O'Morain. Treatment of Helicobacter pylori infection 2016. Helicobacter 2016; 21(S1) doi: 10.1111/hel.12342
|
| 5 |
Hye-Kyung Jung, Seung Joo Kang, Yong Chan Lee, Hyo-Joon Yang, Seon-Young Park, Cheol Min Shin, Sung Eun Kim, Hyun Chul Lim, Jie-Hyun Kim, Su Youn Nam, Woon Geon Shin, Jae Myung Park, Il Ju Choi, Jae Gyu Kim, Miyoung Choi. Evidence-based Guidelines for the Treatment of Helicobacter pylori Infection in Korea: 2020 Revised Edition. The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2020; 20(4) doi: 10.7704/kjhugr.2020.0045
|
| 6 |
Zhi-Qiang Song, Jian Liu, Li-Ya Zhou. Hybrid Therapy Regimen for Helicobacter Pylori Eradication. Chinese Medical Journal 2016; 129(8) doi: 10.4103/0366-6999.179803
|
| 7 |
Javier P. Gisbert, Javier Molina-Infante, Javier Amador, Fernando Bermejo, Luis Bujanda, Xavier Calvet, Manuel Castro-Fernández, Antonio Cuadrado-Lavín, J. Ignasi Elizalde, Emili Gene, Fernando Gomollón, Ángel Lanas, Carlos Martín de Argila, Fermín Mearin, Miguel Montoro, Ángeles Pérez-Aisa, Emilio Pérez-Trallero, Adrián G. McNicholl. IV Spanish Consensus Conference on Helicobacter pylori infection treatment. Gastroenterología y Hepatología (English Edition) 2016; 39(10) doi: 10.1016/j.gastre.2016.11.007
|
| 8 |
Chih-Chieh Huang, Kuo-Wang Tsai, Tzung-Jiun Tsai, Ping-I Hsu. Update on the first-line treatment for Helicobacter pylori infection - a continuing challenge from an old enemy. Biomarker Research 2017; 5(1) doi: 10.1186/s40364-017-0103-x
|
| 9 |
Ping-I Hsu, Kuan-Yang Chen, Wei-Chen Tai, Jyh-Chin Yang, Feng-Woei Tsay, Yu-Hwa Liu, Chien-Lin Chen, Chia-Long Lee, Hong-Zen Yeh, Chao-Hung Kuo, Seng-Kee Chuah, Hsi-Chang Lee, Chang-Bih Shie, Sz-Iuan Shiu, John Y. Kao, Yoshio Yamaoka, David Y. Graham, Deng-Chyang Wu. Hybrid, High-Dose Dual and Bismuth Quadruple Therapies for First-Line Treatment of Helicobacter pylori Infection in Taiwan: A Multicenter, Open-Label, Randomized Trial. American Journal of Gastroenterology 2023; 118(7) doi: 10.14309/ajg.0000000000002255
|
| 10 |
Wei-Chen Tai, Shih-Cheng Yang, Chih-Chien Yao, Cheng-Kun Wu, An-Che Liu, Chen-Hsiang Lee, Yuan-Hung Kuo, Seng-Kee Chuah, Chih-Ming Liang. The Efficacy and Safety of 14-day Rabeprazole Plus Amoxicillin High Dose Dual Therapy by Comparing to 14-day Rabeprazole-Containing Hybrid Therapy for the Naïve Helicobacter pylori Infection in Taiwan: A Randomized Controlled Trial. Infectious Diseases and Therapy 2023; 12(5) doi: 10.1007/s40121-023-00811-3
|
| 11 |
Ping-I Hsu, Feng-Woei Tsay, David Y. Graham, Tzung-Jiun Tsai, Kuo-Wang Tsai, John Y. Kao, Nan-Jing Peng, Chao-Hung Kuo, Sung-Shuo Kao, Huay-Min Wang, Te-Fu Lin, Deng-Chyang Wu. Equivalent Efficacies of Reverse Hybrid and Bismuth Quadruple Therapies in Eradication of Helicobacter pylori Infection in a Randomized Controlled Trial. Clinical Gastroenterology and Hepatology 2018; 16(9) doi: 10.1016/j.cgh.2018.03.031
|
| 12 |
Huimei Xu, Wancong Wang, Xueni Ma, Rukun Feng, Yujing Su, Long Cheng, Yifan Yang, Dekui Zhang. Comparative efficacy and safety of high-dose dual therapy, bismuth-based quadruple therapy and non-bismuth quadruple therapies for Helicobacter pylori infection: a network meta-analysis. European Journal of Gastroenterology & Hepatology 2021; 33(6) doi: 10.1097/MEG.0000000000001835
|
| 13 |
Maria José Temido, Dara Mbanze, Nuno Almeida, Bárbara Oliveiros, Elisa Gravito-Soares, Pedro Figueiredo. Is hybrid therapy more efficient in the eradication of Helicobacter pylori infection? A systematic review and meta-analysis. Annals of Clinical Microbiology and Antimicrobials 2023; 22(1) doi: 10.1186/s12941-023-00582-2
|
| 14 |
Antonio Mestrovic, Nikola Perkovic, Josko Bozic, Mirela Pavicic Ivelja, Jonatan Vukovic, Goran Kardum, Zeljko Puljiz, Ante Tonkic, Lise Lotte Gluud. Randomised clinical trial comparing concomitant and hybrid therapy for eradication of Helicobacter pylori infection. PLOS ONE 2020; 15(12) doi: 10.1371/journal.pone.0244500
|
| 15 |
Zhiqiang Song, Liya Zhou, Jianzhong Zhang, Lihua He, Peng Bai, Yan Xue. Hybrid Therapy as First‐Line Regimen for Helicobacter pylori Eradication in Populations with High Antibiotic Resistance Rates. Helicobacter 2016; 21(5) doi: 10.1111/hel.12294
|
| 16 |
Hye-Kyung Jung, Seung Joo Kang, Yong Chan Lee, Hyo-Joon Yang, Seon-Young Park, Cheol Min Shin, Sung Eun Kim, Hyun Chul Lim, Jie-Hyun Kim, Su Youn Nam, Woon Geon Shin, Jae Myung Park, Il Ju Choi, Jae Gyu Kim, Miyoung Choi. Evidence based guidelines for the treatment of Helicobacter pylori infection in Korea 2020. The Korean Journal of Internal Medicine 2021; 36(4) doi: 10.3904/kjim.2020.701
|
| 17 |
Shu-Peng Zou, Qian Cheng, Cheng-Yang Feng, Chan Xu, Ming-Hui Sun. Comparative effectiveness of first-line therapies for eradication of antibiotic-resistant <i>Helicobacter pylori</i> strains: A network meta-analysis. World Journal of Clinical Cases 2022; 10(35): 12959-12970 doi: 10.12998/wjcc.v10.i35.12959
|
| 18 |
Hye-Kyung Jung, Seung Joo Kang, Yong Chan Lee, Hyo-Joon Yang, Seon-Young Park, Cheol Min Shin, Sung Eun Kim, Hyun Chul Lim, Jie-Hyun Kim, Su Youn Nam, Woon Geon Shin, Jae Myung Park, Il Ju Choi, Jae Gyu Kim, Miyoung Choi. Evidence-Based Guidelines for the Treatment of <i>Helicobacter pylori</i> Infection in Korea 2020. Gut and Liver 2021; 15(2) doi: 10.5009/gnl20288
|
| 19 |
Yao-Jong Yang, Chung-Tai Wu, Horng-Yih Ou, Chin-Han Lin, Hsiu-Chi Cheng, Wei-Lun Chang, Wei-Ying Chen, Hsiao-Bai Yang, Cheng-Chan Lu, Bor-Shyang Sheu. Ten days of levofloxacin-containing concomitant therapy can achieve effective Helicobacter pylori eradication in patients with type 2 diabetes. Annals of Medicine 2017; 49(6) doi: 10.1080/07853890.2017.1294761
|
| 20 |
Fahad Alsohaibani, Musthafa Peedikayil, Abdulaziz Alshahrani, Ali Somily, Raed Alsulaiman, Nahla Azzam, Majid Almadi. Practice guidelines for the management of Helicobacter pylori infection: The Saudi H. pylori Working Group recommendations. Saudi Journal of Gastroenterology 2023; 29(6) doi: 10.4103/sjg.sjg_288_22
|
| 21 |
Yoen‐Young Chuah, Deng‐Chyang Wu, Seng‐Kee Chuah, Kuan‐Yang Chen, Jyh‐Chin Yang, Chia‐Long Lee, Chien‐Lin Chen, Sz‐Iuan Shiu, Chang‐Bih Shie, Chih‐An Shih, Feng‐Woei Tsay, Yu‐Hwa Liu, Ping‐I Hsu. REAP‐HP survey 2020: Comparing the real‐world practice and expectation in Helicobacter pylori eradication of the Taiwanese gastroenterologists in 2015 and 2020. Helicobacter 2022; 27(6) doi: 10.1111/hel.12931
|
| 22 |
Javier P. Gisbert, Javier Molina-Infante, Javier Amador, Fernando Bermejo, Luis Bujanda, Xavier Calvet, Manuel Castro-Fernández, Antonio Cuadrado-Lavín, J. Ignasi Elizalde, Emili Gene, Fernando Gomollón, Ángel Lanas, Carlos Martín de Argila, Fermín Mearin, Miguel Montoro, Ángeles Pérez-Aisa, Emilio Pérez-Trallero, Adrián G. McNicholl. IV Conferencia Española de Consenso sobre el tratamiento de la infección por Helicobacter pylori. Gastroenterología y Hepatología 2016; 39(10) doi: 10.1016/j.gastrohep.2016.05.003
|
| 23 |
Javier P. Gisbert, Adrian G. McNicholl. Optimization strategies aimed to increase the efficacy of H. pylori eradication therapies. Helicobacter 2017; 22(4) doi: 10.1111/hel.12392
|
| 24 |
Alessia Savoldi, Elena Carrara, David Y. Graham, Michela Conti, Evelina Tacconelli. Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions. Gastroenterology 2018; 155(5) doi: 10.1053/j.gastro.2018.07.007
|
| 25 |
Hye-Kyung Jung, Seung Joo Kang, Yong Chan Lee, Hyo-Joon Yang, Seon-Young Park, Cheol Min Shin, Sung Eun Kim, Hyun Chul Lim, Jie-Hyun Kim, Su Youn Nam, Woon Geon Shin, Jae Myung Park, Il Ju Choi, Jae Gyu Kim, Miyoung Choi. Evidence-Based Guidelines for the Treatment of Helicobacter pylori Infection in Korea: 2020 Revised Edition. The Korean Journal of Medicine 2021; 96(3) doi: 10.3904/kjm.2021.96.3.160
|
| 26 |
Kai‐Pi Cheng, Yao‐Jong Yang, Hao‐Chang Hung, Ching‐Han Lin, Chung‐Tai Wu, Mei‐Hui Hung, Bor‐Shyang Sheu, Horng‐Yih Ou. Helicobacter pylori eradication improves glycemic control in type 2 diabetes patients with asymptomatic active Helicobacter pylori infection. Journal of Diabetes Investigation 2019; 10(4) doi: 10.1111/jdi.12991
|